// App-Quantinova.ai

PO1833 : The NefIgArd trial: The Effect of Nefecon® (Budesonide) in Patients with Primary IgA Nephropathy at Risk of Developing ESRD

Researchers

Presenter

  • Barratt Jonathan

Principal Investigators

  • Kristensen Jens

  • Stone AndrewM

Medical Centers

  • Mayer IgA Nephropathy Laboratory University of Leicester UK Leicester United Kingdom

  • Calliditas Therapeutics AB Stockholm Sweden

Locations

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

Disease

  • IgA nephropathy

  • Albuminuria

  • End stage renal disease

Biomarkers

  • Cancer antigen 15-3

  • Cluster of differentiation 79A

Drug/Treatment

  • Angiotensin II

  • Budesonide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved